Search Results 1891-1900 of 17240 for magnesiummagnesium

1. Rem-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS - Mayo Clinic

   Participation eligibility · Clinically significant active infection. · Current or expected need for daily systemic corticosteroid therapy ≥ 10 mg of prednisone ...

2. RA-PRO PRAGMATIC TRIAL - Mayo Clinic

   Glucocorticoid and NSAID treatment - If receiving glucocorticoids (≤ 10 mg/day of prednisone of equivalent) or NSAIDs, on stable doses for ≥ 2 weeks prior to ...

3. A Study to Evaluate 68Ga- PSMA-Dual Contrast PET/MRI and PET/CT for Hepatocellular Carcinoma - Mayo Clinic

   - Bilirubin > 3.0 mg/dL, which is a contraindication for Gadoxetate, the MRI contrast agent (relevant to PET/MRI) - Patients with glomerular filtration rate ...

4. A Phase 1-2 Multi-Center Study Evaluating Axicabtagene Ciloleucel in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) - Mayo Clinic

   Total bilirubin ≤ 1.5 mg/dl, except in subjects with Gilbert's syndrome;; Cardiac ejection fraction ≥ 50%, no evidence of pericardial effusion as ...

5. Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen - Mayo Clinic

   (Participants with previously diagnosed Gilbert's syndrome not accompanied by other hepatobiliary disorders and associated with TB <3.5 mg/dL [<51.3 µmol/L] ...

6. A Study to Compare the Effectiveness and Safety of Emixustat Hydrochloride with Placebo to Treat Macular Atrophy Secondary to Stargadt Disease - Mayo Clinic

   Serum creatinine > 2.0 mg/dL;; Estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2;; Impaired hematologic function: hemoglobin < 11 g/dL ...

7. A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough - Mayo Clinic

   - Mannitol CDR ≥ 12 coughs/100 mg determined at screening visit mannitol challenge test - For women of childbearing potential: agreement to remain ...

8. A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies or AML - Mayo Clinic

   corticosteroids (≤20 mg/day of prednisone or equivalent), topical, or inhaled corticosteroids 2. During study therapy, subjects may use systemic, topical ...

9. A Study of Poziotinib in Patients with NSCLC With EGFR or HER2 Exon 20 Insertion Mutation - Mayo Clinic

   Total bilirubin ≤ 2 mg/dL; if hepatic metastases are present, ≤ 2.5 × ULN;; SGOT (AST) and SGPT (ALT) ≤ 2.5×ULN with the following exception; Patients ...

10. Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) - Mayo Clinic

    ... mg/m\^2 daunorubicin or equivalent. Prior hypomethylating agent (HMA) exposure is allowed, as long as not for AML diagnosis * Participants must not have ...